Health Equity & Access Weekly Roundup: May 22, 2026

5 Things to Pay Attention to During Women's Health Month

In 2026, women's health is experiencing a transformative shift driven by unprecedented clinical innovation, evolving policies, and increased data collection across 5 critical areas. Recent evidence has recalibrated menopause management to emphasize individualized, transdermal hormone therapies initiated within a specific age window, which also shows potential for reducing Alzheimer disease and dementia risks when implemented during midlife. Meanwhile, reproductive care remains highly volatile as the Supreme Court temporarily preserved telehealth and mail access to mifepristone amid ongoing lower-court battles. Concurrently, maternal health is becoming more equitable through the mainstream adoption and expanding Medicaid coverage of evidence-based doula care, which significantly reduces cesarean and preterm delivery rates by addressing social determinants of health. Finally, a data revolution powered by wearable technology is mapping the impact of menstrual cycles on cardiovascular and neurological functions, providing health care stakeholders with a new frontier for early risk stratification and personalized wellness.

HHS Secretary RFK Jr Dismisses USPSTF Leadership, Signaling Overhaul of Preventive Care Mandates

The recent firing of the US Preventive Services Task Force’s (USPSTF) top 2 leaders by HHS Secretary Robert F. Kennedy Jr has sparked widespread concern among public health officials, who warn it undermines the nonpartisan credibility of federal medical guidance. Supported by a June 2025 Supreme Court ruling that validated the administration's sweeping authority over the panel, Kennedy defended the unexpected terminations as a routine review to ensure operational clarity and confidence, rather than a reflection of performance. However, critics argue the move is part of a broader pattern of disruptive federal health overhauls that have already delayed meetings and stalled critical clinical recommendations. Because the USPSTF's evidence-based ratings legally mandate free coverage for vital screenings under the Affordable Care Act (ACA), this sudden leadership shakeup introduces substantial regulatory and financial uncertainty for managed care executives, clinicians, and millions of insured Americans.

ACA Marketplace Deductibles Surge $1000 in 2026 as Enhanced Tax Credits Expire

The expiration of enhanced ACA premium tax credits at the end of 2025 has triggered a historic disruption in the individual insurance market, marked by a record 37% surge in average marketplace deductibles to $3786 and an expected enrollment collapse of nearly 5 million people for 2026. According to recent KFF analyses, the dramatic rise in deductibles was primarily driven by cash-strapped consumers migrating from silver to cheaper bronze plans, while average monthly premium payments simultaneously climbed 58% to $178. This financial strain has caused sign-ups to drop to 23.1 million—the sharpest single-year decline in the program's history—with young adults and middle-income individuals above the subsidy cliff exiting the market at the highest rates. Furthermore, the impact is highly regional, with federally facilitated exchanges in states like North Carolina and Ohio seeing steep enrollment drops, while states with state-based exchanges and supplemental financial assistance, such as New Mexico, have successfully insulated consumers and grown their enrollment.

Financial Toxicity Independently Predicts QOL in Hidradenitis Suppurativa

A cross-sectional survey study reveals that financial strain is an independent predictor of a lower quality of life for patients with hidradenitis suppurativa (HS), particularly among those with severe disease burden, psychiatric comorbidities, and biologic drug prescriptions. Utilizing the Comprehensive Score for Financial Toxicity–Functional Assessment of Chronic Illness Therapy and Dermatology Life Quality Index measurement tools on a cohort of 114 patients, researchers at the University of Virginia found that greater out-of-pocket health care costs significantly compounded the severe quality-of-life impairments already characteristic of the condition. Although biologic therapies and multisite lesion involvement were associated with heightened financial hardship, patients with a family history of HS experienced lower financial toxicity, potentially due to earlier disease recognition and shared coping strategies. Ultimately, the authors conclude that incorporating financial counseling and targeted economic support into multidisciplinary HS care is vital to mitigating financial toxicity and improving overall patient-centered outcomes.

One-Third of Patients With Vitiligo Go Untreated After Diagnosis

According to a new large retrospective cohort study, nearly one-third of patients diagnosed with vitiligo go entirely untreated, while those who do receive care frequently cycle through multiple, short-lived treatment regimens. Analyzing deidentified data from over 24,900 patients, researchers found that the median duration for first- and second-line therapies—most commonly topical or oral corticosteroids and topical calcineurin inhibitors—lasted only 1.8 to 4.1 months, which is often insufficient to evaluate clinical efficacy. The study revealed significant age-based variations, with pediatric patients primarily receiving topical treatments and adults frequently prescribed oral corticosteroids, although a high variability in treatment sequencing and a lack of standardization persisted across all groups. Ultimately, the authors attribute these abbreviated treatment durations and inconsistent prescribing patterns to restricted long-term therapeutic options, insurance and access barriers, and the substantial psychosocial burden of the disease, which includes high rates of anxiety and depression, particularly when high-impact areas like the face are affected.